Case Studies

Regulatory Strategy: Development of 505(b)(2) Roadmap Enables Data-Driven Go/No-Go Decision for Rare-Disease Candidate

Project Overview

A small pharmaceutical company acquired a compound with extensive Phase 2b cardiovascular data and sought to repurpose the molecule for a rare-disease indication. To succeed, the company needed to design a regulatory strategy that would justify the 505(b)(2) pathway while minimizing clinical and financial risk.

The Challenge

The client lacked a clear regulatory and clinical roadmap for repositioning an existing molecule toward a rare disease.

Limited internal resources and constrained budgets required a strategic, data-driven plan that maximized reuse of existing assets.

Timelines were tight due to investor expectations and competitive market pressures in the rare-disease space.

Our Approach

Conducted a comprehensive analysis of prior cardiovascular clinical study reports, safety and efficacy data, and relevant pharmacology to identify data suitable for cross-reference.

Reviewed public-domain literature and rare-disease precedent cases to map potential regulatory and scientific justification for a 505(b)(2) submission.

Developed a Product Development Plan (PDP) integrating a clear 505(b)(2) regulatory roadmap, clinical-development design, and cost-efficient execution strategy.

Advised on budget-optimized clinical program design, ensuring feasibility for a smaller sponsor while maintaining compliance and scientific rigor.

Delivered a comprehensive market and competitive analysis, assessing pricing and reimbursement dynamics, payor and formulary access potential, and profitability outlook.

Outcome / Impact

Delivered a clear regulatory, clinical, and market strategy enabling the client to make an informed, data-driven investment decision.

Comprehensive commercial and profitability assessments revealed that pursuing a costly Phase 3 program would not yield a viable return on investment.

Based on NGT’s analysis, the client and investors opted not to proceed with Phase 3 development—avoiding substantial financial exposure and reallocating resources to more promising pipeline opportunities.